S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:RETA

Reata Pharmaceuticals - RETA News Today

$90.92
+0.90 (+1.00%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$88.01
$93.16
50-Day Range
$30.85
$93.17
52-Week Range
$18.47
$95.00
Volume
851,682 shs
Average Volume
1.13 million shs
Market Capitalization
$3.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$96.89
Get Reata Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.


RETA Media Mentions By Week

RETA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RETA
News Sentiment

0.19

0.47

Average
Medical
News Sentiment

RETA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RETA Articles
This Week

12

1

RETA Articles
Average Week

SourceHeadline
marketbeat.com logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) to Post FY2022 Earnings of ($8.54) Per Share, Cantor Fitzgerald Forecasts
marketbeat.com - March 30 at 6:52 AM
marketbeat.com logoQuent Capital LLC Acquires New Holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
marketbeat.com - March 30 at 5:28 AM
marketbeat.com logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Average Recommendation of "Moderate Buy" by Brokerages
marketbeat.com - March 27 at 4:41 AM
marketbeat.com logoThe Stock That Tripled in a Day...And May Not Be Done
marketbeat.com - March 7 at 6:55 AM
MarketBeat logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Rating of "Moderate Buy" by Analysts
americanbankingnews.com - April 1 at 4:44 AM
MarketBeat logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) Forecasted to Earn FY2022 Earnings of ($8.54) Per Share
americanbankingnews.com - April 1 at 1:26 AM
MarketBeat logoReata Pharmaceuticals (NASDAQ:RETA) PT Raised to $138.00
americanbankingnews.com - March 29 at 2:46 AM
markets.businessinsider.com logoWhere Reata Pharmaceuticals Stands With Analysts
markets.businessinsider.com - March 27 at 1:46 PM
businesswire.com logoREATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc ...
businesswire.com - March 5 at 10:07 PM
businesswire.com logoREATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
businesswire.com - March 3 at 9:40 PM
bizjournals.com logoPlano-based Reata Pharmaceuticals secures FDA approval for first-of-its-kind ultra-rare disease treatment
bizjournals.com - March 2 at 2:35 PM
finance.yahoo.com logoWhy Reata Pharmaceuticals Stock Skyrocketed This Week
finance.yahoo.com - March 2 at 2:35 PM
finance.yahoo.com logoReata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
finance.yahoo.com - March 2 at 9:35 AM
msn.com logoHot Stocks: RETA nearly triples on FDA approval; FSLR surges on earnings; NVAX, MQ plunge
msn.com - March 1 at 6:33 PM
reuters.com logoU.S. FDA approves Reata's rare genetic disorder drug
reuters.com - March 1 at 8:32 AM
msn.com logoReata Skyrockets on FDA Approval for Friedreich’s Ataxia Drug
msn.com - March 1 at 8:32 AM
barrons.com logoReata Soars on Approval for Rare Disorder Drug. Its Pipeline Value Impresses Analysts.
barrons.com - March 1 at 8:32 AM
nasdaq.com logoFirst Week of April 21st Options Trading For Reata Pharmaceuticals (RETA)
nasdaq.com - February 19 at 6:17 PM
finance.yahoo.com logoThe Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
finance.yahoo.com - February 1 at 12:40 PM
forbes.com logoReata Pharmaceuticals
forbes.com - January 25 at 1:13 PM
fool.com logoReata Pharmaceuticals (NASDAQ: RETA)
fool.com - January 14 at 11:35 PM
finance.yahoo.com logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript
finance.yahoo.com - December 31 at 6:20 PM
finance.yahoo.com logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript
finance.yahoo.com - December 31 at 6:20 PM
finance.yahoo.com logoReata Pharmaceuticals (NASDAQ:RETA) shareholders have endured a 84% loss from investing in the stock three years ago
finance.yahoo.com - December 22 at 12:21 PM
finance.yahoo.com logoReata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
finance.yahoo.com - November 9 at 12:36 PM
seekingalpha.com logoReata rises 15% as omaveloxolone moves ahead in FDA review process; plans EU filing
seekingalpha.com - November 8 at 2:08 PM
finance.yahoo.com logoWhy Reata Pharmaceuticals Stock Is Soaring Today
finance.yahoo.com - November 8 at 2:08 PM
finance.yahoo.com logoReata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
finance.yahoo.com - November 8 at 9:07 AM
finance.yahoo.com logoReata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
finance.yahoo.com - November 1 at 2:15 AM
finance.yahoo.com logo2 On-Fire Biotech Stocks That Are Crushing the Bear Market
finance.yahoo.com - October 31 at 11:20 AM
investorplace.com logoWhy Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?
investorplace.com - October 14 at 3:02 PM
markets.businessinsider.com logoNasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply
markets.businessinsider.com - October 14 at 1:22 PM
nasdaq.com logoReata Pharma Spikes 15%
nasdaq.com - October 14 at 1:22 PM
nasdaq.com logoReata : FDA Doesn't Plan To Hold Meeting To Discuss NDA For Omaveloxolone For Friedreich's Ataxia
nasdaq.com - October 14 at 3:04 AM
finance.yahoo.com logoReata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia
finance.yahoo.com - October 13 at 5:01 PM
seekingalpha.com logoRETA Reata Pharmaceuticals, Inc.
seekingalpha.com - October 1 at 11:18 AM
nasdaq.com logoInvestors in Reata Pharmaceuticals (NASDAQ:RETA) from a year ago are still down 76%, even after 13% gain this past week
nasdaq.com - September 13 at 9:43 PM
benzinga.com logoMoore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm
benzinga.com - September 12 at 3:39 PM
reuters.com logoReata Pharmaceuticals Inc
reuters.com - September 10 at 12:53 PM
benzinga.com logo2RETA : Reata Pharmaceuticals Whale Trades Spotted
benzinga.com - September 8 at 3:32 PM
finance.yahoo.com logoWhy Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?
finance.yahoo.com - September 8 at 3:32 PM
finance.yahoo.com logoReata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
finance.yahoo.com - September 6 at 5:59 PM
finance.yahoo.com logoTime To Worry? Analysts Just Downgraded Their Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Outlook
finance.yahoo.com - August 14 at 9:59 AM
finance.yahoo.com logoReata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
finance.yahoo.com - August 9 at 7:20 AM
seekingalpha.com logoReata Pharmaceuticals, Inc.'s (RETA) CEO Warren Huff on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 4:12 PM
seekingalpha.com logoReata drops 33%, most since December; Goldman sees favorable risk reward profile
seekingalpha.com - August 8 at 4:12 PM
finance.yahoo.com logoReata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 8 at 4:12 PM
finance.yahoo.com logoWhy Reata Pharma Shares Are Trading Lower After Q2 Earnings Update?
finance.yahoo.com - August 8 at 4:12 PM
benzinga.com logoReata Pharmaceuticals Earnings Preview
benzinga.com - August 5 at 12:45 PM
seekingalpha.com logoReata extends gains as Citi welcomes regulatory win for lead asset
seekingalpha.com - May 27 at 4:38 PM
finance.yahoo.com logoFDA grants priority review to Reata's rare disease drug
finance.yahoo.com - May 26 at 7:01 PM
MarketBeat logoReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - May 6 at 8:52 AM
finance.yahoo.com logoReata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
finance.yahoo.com - May 2 at 8:24 PM
apnews.com logoMoore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm
apnews.com - April 8 at 4:19 AM
Get Reata Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:RETA) was last updated on 4/1/2023 by MarketBeat.com Staff